Vacunación contra la gripe aviar en los zoológicos de selwomarina y selwoaventura: ventajas y desventajas

Durante el mes de agosto de 2006 los parques zoológicos Selwomarina y Selwoaventura, situados en Málaga, decidieron vacunar a sus aves frente a la gripe aviar. En este trabajo se describen los datos obtenidos y estudios realizados sobre este tema con el que estuvimos vinculadas directamente al coincidir nuestra estancia en dichos parques en estas fechas

Draft Genome Sequence of the Moderately Halophilic Bacterium Pseudoalteromonas ruthenica Strain CP76

Pseudoalteromonas ruthenica strain CP76, isolated from a saltern in Spain, is a moderately halophilic bacterium belonging to the Gammaproteobacteria. Here we report the draft genome sequence, which consists of a 4.0-Mb chromosome, of this strain, which is able to produce the extracellular enzyme haloprotease CPI

First-Trimester Sequential Screening for Preeclampsia Using Angiogenic Factors : Study Protocol for a Prospective, Multicenter, Real Clinical Setting Study

The incidence of preeclampsia (PE) is about 2-8%, making it one of the leading causes of perinatal morbidity and maternal mortality in the world. Early prophylactic low dose administration (150 mg) of acetylsalicylic acid is associated with a significant reduction in the incidence of early-onset PE, intrauterine growth restriction (IUGR), and neonatal mean stay in the intensive care unit (ICU). Universal implementation of a first-trimester screening system including angiogenic and antiangiogenic markers [the Placental Growth Factor (PlGF) and/or soluble fms-like Tyrosine Kinase-1 (sFlt-1)] has shown a prediction rate of 90% for early-onset PE but entails a high financial cost. The aim of this study is to determine the predictive and preventive capacity of a universal PE first-trimester two-step sequential screening model, determining the PlGF only in patients previously classified as intermediate risk by means of a multivariate model based on resources already used in the standard pregnancy control, in a real clinical setting. We hypothesize that this screening model will achieve similar diagnostic performance as the universal determination of PlGF but at a lower economic cost. This is a prospective, multicentric, cohort study in a real-world clinical setting. Every singleton pregnancy will be recruited at the routine first pregnancy visit. In a first step, the first-trimester risk of PE will be calculated using a multivariate Gaussian distribution model, based on medical history, mean blood pressure, Pregnancy-Associated Plasma Protein A (PAPP-A), and Uterine Artery Doppler Pulsatility Index (UTPI). Patients will be classified into three risk groups for PE: (1) risk ≥ 1/50, high-risk with no further testing (blinded PlGF); (2) risk between 1/51 and 1/500, medium-risk requiring further testing; and (3) risk ≤ 1/501, low-risk with no further testing. In a second step, the PlGF will only be determined in those patients classified as intermediate risk after this first step, and then reclassified into high- or low-risk groups. Prophylactic administration of aspirin (150 mg/day) will be prescribed only in high risk patients. As a secondary objective, sFlt-1 values will be blindly determined in patients with high and intermediate risk to assess its potential performance in the screening for PE. The study will be conducted in accordance with the principles of Good Clinical Practice. This study is approved by the Aragon Research Ethics Committee (CEICA) on 3 July 2020 (15/2020). , identifier: NCT04767438

La fosfoenolpiruvato carboxilasa (PEPC): enzima clave de los metabolismos fotosintéticos C4 y CAM

http://digital.csic.es/bitstream/10261/29768/13/echevarria.pdfLa fosfoenolpiruvato carboxilasa (PEPC; EC 4.1.1.31) cataliza la β-carboxilación del fosfoenolpiruvato (PEP) en presencia de HCO3 - y Mg2+, para producir oxaloacetato (OAA) y Pi (Chollet et al., 1996). La PEPC está ampliamente distribuida en plantas, algas verdes y microorganismos pero ausente en levaduras y animales (Chollet et al., 1996). En plantas vasculares su papel estelar está relacionado con la fotosíntesis C4 y CAM («Crassulacean acid metabolism»), sin embargo desempeña otras funciones como la anaplerótica, en relación a la síntesis de proteínas, homeostasis del pH citosólico, electroneutralidad y osmolaridad. Está formada por una pequeña familia multigénica algunos de cuyos representantes están regulados a nivel transcripcional por factores como luz, hormonas y metabolitos (Chollet et al., 1996; Vidal y Chollet, 1997). La naturaleza alostérica de la enzima permite una regulación fina en relación a diferentes ambientes metabólicos. La PEPC está regulada por fosforilación reversible, proceso ligado a una cascada de transducción de señales de alta complejidad. En la actualidad es uno de los mejores modelos de señalización descritos en plantas. Este capítulo se centra en los eventos relacionados con este proceso en plantas C4 y CAM, los dos sistemas mejor estudiados en la actualidad (Chollet et al., 1996; Echevarría y Vidal, 2003; Izui et al., 2004; Nimmo, 2000; Vidal y Chollet, 1997).Phosphoenolpyruvate carboxylase (EC 4.1.1.31, PEPC) catalyzes the b-carboxylation of phosphoenolpyruvate (PEP) by HCO3 - in the presence of Mg2+ to yiel oxaloacetate and Pi (Chollet et al., 1996). PEPC is a widely distributed enzyme in plants, green algae and micro-organisms but absent in yeast and animals (Chollet et al., 1996). In higher plants, it catalyses a pivotal reaction related to such important processes as C4 and Crassulacean acid metabolism (CAM) photosynthesis, the anaplerotic pathway linked to amino acid synthesis, homeostasis of cytosolic pH, electroneutrality and osmolarity. PEPC belongs to a small multigenic family (Chollet et al., 1996; Vidal y Chollet, 1997). At the transcriptional level, some PEPC genes respond to external and internal factors (light, hormones and metabolites), while at the protein level, the allosteric nature of the enzyme allows its activity to be fine-tuned in relation to a varying metabolic environment. PEPC undergoes a posttranslational control by a phosphorylation process linked to a highly complex signal transduction cascade. Today, it is one of the best-described models of plant signaling. This chapter will focus on what is known about these processes in leaves of C4 and CAM plants, the two systems that have been studied in detail so far (Chollet et al., 1996; Echevarría y Vidal, 2003; Izui et al., 2004; Nimmo, 2000; Vidal y Chollet, 1997)

First-Trimester Sequential Screening for Preeclampsia Using Angiogenic Factors: Study Protocol for a Prospective, Multicenter, Real Clinical Setting Study

IntroductionThe incidence of preeclampsia (PE) is about 2–8%, making it one of the leading causes of perinatal morbidity and maternal mortality in the world. Early prophylactic low dose administration (150 mg) of acetylsalicylic acid is associated with a significant reduction in the incidence of early-onset PE, intrauterine growth restriction (IUGR), and neonatal mean stay in the intensive care unit (ICU). Universal implementation of a first-trimester screening system including angiogenic and antiangiogenic markers [the Placental Growth Factor (PlGF) and/or soluble fms-like Tyrosine Kinase-1 (sFlt-1)] has shown a prediction rate of 90% for early-onset PE but entails a high financial cost. The aim of this study is to determine the predictive and preventive capacity of a universal PE first-trimester two-step sequential screening model, determining the PlGF only in patients previously classified as intermediate risk by means of a multivariate model based on resources already used in the standard pregnancy control, in a real clinical setting. We hypothesize that this screening model will achieve similar diagnostic performance as the universal determination of PlGF but at a lower economic cost.Methods and AnalysisThis is a prospective, multicentric, cohort study in a real-world clinical setting. Every singleton pregnancy will be recruited at the routine first pregnancy visit. In a first step, the first-trimester risk of PE will be calculated using a multivariate Gaussian distribution model, based on medical history, mean blood pressure, Pregnancy-Associated Plasma Protein A (PAPP-A), and Uterine Artery Doppler Pulsatility Index (UTPI). Patients will be classified into three risk groups for PE: (1) risk ≥ 1/50, high-risk with no further testing (blinded PlGF); (2) risk between 1/51 and 1/500, medium-risk requiring further testing; and (3) risk ≤ 1/501, low-risk with no further testing. In a second step, the PlGF will only be determined in those patients classified as intermediate risk after this first step, and then reclassified into high- or low-risk groups. Prophylactic administration of aspirin (150 mg/day) will be prescribed only in high risk patients. As a secondary objective, sFlt-1 values will be blindly determined in patients with high and intermediate risk to assess its potential performance in the screening for PE.Ethics and DisseminationThe study will be conducted in accordance with the principles of Good Clinical Practice. This study is approved by the Aragon Research Ethics Committee (CEICA) on 3 July 2020 (15/2020).Clinical Trial RegistrationClinicalTrials.gov, identifier: NCT04767438

Huariquea.pe

El presente modelo de negocio Huariquea.pe tiene como finalidad brindar el servicio de ubicación de huariques en el Perú, a través del cual las personas encuentren los lugares donde se pueda comer bien, a buen precio y en un ambiente casero, es decir, ese “rinconcito” donde la comida es muy buena. En la actualidad no existe una aplicación o página web que permita encontrar estos lugares, donde aparezca información como su carta, dirección, teléfono y ubicación por GPS. Por ello, nuestro servicio busca satisfacer esas necesidades y darles a nuestros clientes información de calidad, para que puedan tener la mejor experiencia buscando lugares de buen comer. Por otra parte, para poder sustentar este negocio, desarrollaremos la siguiente estructura: descripción de la idea de negocio, análisis interno y externo, investigación de mercado, plan de marketing, plan de operaciones, estructura organizacional y RRHH, y finalmente el plan económico, en donde se detallará la proyección de las actividades de huariquea.pe en 5 años.The purpose of this business model, Huariquea.pe, is to provide the huariques location service in Peru, through which people find places where they can eat well, at a good price and in a home environment, that is, that "Little corner" where the food is very good. Currently there is no application or web page that allows you to find these places, where information such as your letter, address, telephone number and GPS location appears. For this reason, our service seeks to satisfy those needs and give our clients quality information, so that they can have the best experience looking for places to eat good. On the other hand, in order to sustain this business, we will develop the following structure: description of the business idea, internal and external analysis, market research, marketing plan, operations plan, organizational structure and HR, and finally the economic plan, where the projection of the activities of huariquea.pe in 5 years will be detailedTrabajo de investigació

Seguimiento y mejora de las asignaturas de segundo curso del Grado en Ingeniería Informática durante el curso 2013-2014

En esta memoria se describe el trabajo de la red docente para el seguimiento y control de calidad de las asignaturas del segundo curso del Grado en Ingeniería Informática impartido en la Escuela Politécnica Superior de la Universidad de Alicante. En esta edición, el trabajo de la red se ha centrado en el estudio de las necesidades formativas y los contenidos impartidos en las asignaturas. El resultado ha sido la creación de un grafo de dependencias entre asignaturas de segundo y primer curso (y de segundo curso entre sí), un mapa de necesidades formativas para acceder a las asignaturas de segundo curso y un mapa de los contenidos impartidos en éstas. Asimismo, se ha elaborado un calendario on-line de evaluaciones para el curso 2014-2015

Growth patterns and breast milk/infant formula energetic efficiency in healthy infants up to 18 months of life: the COGNIS study

This project has been funded by Laboratorios Ordesa, S. L. Contract University of Granada General Foundation, No. 3349 and SMARTFOODS (CIEN) Contract University of Granada General Foundation, No. 4003, Spanish Ministry of Economy, Industry and Competitiveness, and partially funded by HORIZON 2020 EU DynaHEALTH Project (GA No.633595). N. S-V. has been granted with a scholarship from Fundaci ' on Carolina, Madrid, Spain.Type of feeding during early life influences growth trajectory and metabolic risk at later ages. Modifications in infant formula composition have led to evaluate their effects on growth and energetic efficiency (EE) compared with breast-feeding. Main goal was to analyse type of feeding potential effects during first months of life, plus its EE, on growth patterns in healthy formula fed (standard infant formula (SF) vs. experimental infant formula enriched with bioactive nutrients (EF)) and breastfed (BF) infants participating in the COGNIS RCT (http://www.ClinicalTrials.gov, Identifier: NCT02094547) up to 18 months of age. Infants follow-up to 18 months of age (n 141) fed with a SF (n 48), EF(n 56), or BF (n 37), were assessed for growth parameters using WHO standards. Growth velocity (GV) and catch-up were calculated to identify growth patterns. EE of breast milk/infant formula was also estimated. Infants' growth at 6 months showed higher length and lower head circumference gains in SF and EF infants than BF infants. Both weight-for-length and weight-for-age catch-up growth showed significant differences in formula fed groups compared with the BF. No significant differences in GV or catch-up were found at 6-12 and 12-18 months. Regarding EE, infant formula groups showed significantly lower weight and length gains/g of milk protein, and higher weight and length gains/g of milk lipids, than the BF infants. GV during first 6 months, which may be influenced by feeding, seems to be the main predictor of subsequent growth trajectory. Breast-feeding may have positive effects on growth programming due to its nutrients' EE.Laboratorios Ordesa, S. L. Contract University of Granada General Foundation 3349SMARTFOODS (CIEN) Contract University of Granada General Foundation 4003Spanish Ministry of Economy, Industry and CompetitivenessHORIZON 2020 EU DynaHEALTH Project 633595Fundacion Carolina, Madrid, Spai

Cortical Visual Evoked Potentials and Growth in Infants Fed with Bioactive Compounds-Enriched Infant Formula: Results from COGNIS Randomized Clinical Trial

Postnatal nutrition is essential for growth and neurodevelopment. We analyzed the influence of a new enriched-infant formula with bioactive compounds on growth, neurodevelopment, and visual function (VF) in healthy infants during their first 18 months of life. A total of 170 infants were randomized in the COGNIS randomized clinical trial (RCT) to receive a standard infant formula (SF = 85) or a new experimental infant formula supplemented with functional nutrients (EF = 85). As a control, 50 breastfed infants (BF) were enrolled. Growth patterns were evaluated up to 18 months of life; neurodevelopment was assessed by general movements at 2, 3, and 4 months; VF was measured by cortical visual evoked potentials at 3 and 12 months. No differences in growth and neurodevelopment were found between groups. Regarding VF, SF and EF infants presented prolonged latencies and lower amplitudes in the P100 wave than BF infants. In the EF group, a higher percentage of infants presented response at 7 1/2' of arc at 12 months compared to 3 months of age; a similar proportion of BF and EF infants presented responses at 7 1/2' of arc at 12 months of age. Early nutritional intervention with bioactive compounds could narrow the gap in growth and neurodevelopment between breastfed and formula-fed infants.This project has been funded by Ordesa Laboratories, S.L. Contract University of Granada General Foundation, No. 3349 and SMARTFOODS (CIEN) Contract University of Granada General Foundation, No. 4003, Spanish Ministry of Economy, Industry and Competitiveness; funded in part by HORIZON 2020 EU DynaHEALTH Project (GA No.633595)

Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients

The impact of human leukocyte antigen (HLA)-mismatching on the early appearance of subclinical inflammation (SCI) in low-immunological-risk kidney transplant (KT) recipients is undetermined. We aimed to assess whether HLA-mismatching (A-B-C-DR-DQ) is a risk factor for early SCI. As part of a clinical trial (Clinicaltrials.gov, number NCT02284464), a total of 105 low-immunological-risk KT patients underwent a protocol biopsy on the third month post-KT. As a result, 54 presented SCI, showing a greater number of total HLA-mismatches (p = 0.008) and worse allograft function compared with the no inflammation group (48.5 ± 13.6 vs. 60 ± 23.4 mL/min; p = 0.003). Multiple logistic regression showed that the only risk factor associated with SCI was the total HLA-mismatch score (OR 1.32, 95%CI 1.06-1.64, p = 0.013) or class II HLA mismatching (OR 1.51; 95%CI 1.04-2.19, p = 0.032) after adjusting for confounder variables (recipient age, delayed graft function, transfusion prior KT, and tacrolimus levels). The ROC curve illustrated that the HLA mismatching of six antigens was the optimal value in terms of sensitivity and specificity for predicting the SCI. Finally, a significantly higher proportion of SCI was seen in patients with >6 vs. ≤6 HLA-mismatches (62.3 vs. 37.7%; p = 0.008). HLA compatibility is an independent risk factor associated with early SCI. Thus, transplant physicians should perhaps be more aware of HLA mismatching to reduce these early harmful lesions